ADXN - CONSENSUS CO - Addex Therapeutics

Addex Therapeutics (ADXN) is a biotech startup without steady income, whose revenues are limited to payments from counterparties, with the current figure standing at 22.96. The share price history on GURU.Markets reflects the impact of the Dipraglurant program's success and the collaboration with Indivior in the field of addiction treatment. Addex Therapeutics is developing a unique brain receptor tuning system, which enables the treatment of dyskinesia with minimal negative effects on the body.

Long-term investing requires filtering market noise through an analysis of fundamental upside, which is determined by analysts' median target price as a weighted average forecast of the asset's value. For Addex Therapeutics (ADXN), this indicator weighs market undervaluation against the brand's scientific authority in developing selective modulators for treating neurological disorders, allowing investors to assess the probability of optimistic capitalization growth scenarios.